Blister agents

Synedgen Receives Supplemental NEI Funding to Identify Lead Development Candidate for Ocular Mustard Gas Injury Program

Retrieved on: 
Thursday, October 29, 2020

The additional funding from the NEI provides resources to optimize down-selection to a lead molecule to advance into animal studies.

Key Points: 
  • The additional funding from the NEI provides resources to optimize down-selection to a lead molecule to advance into animal studies.
  • We are thankful for the NEIs continued support of our ocular mustard gas injury program, which has added a number of active novel glycopolymers to our library, said Shenda Baker, Ph.D., President and Chief Executive Officer of Synedgen.
  • Synedgens ocular mustard gas injury program supports development of a potential treatment for military and civilian ocular injuries caused by sulfur mustard (SM).
  • Using this data, Synedgen plans to select a lead development candidate to progress into animal trials.